Cargando…

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations

PURPOSE: Most epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are resistant to tyrosine kinase inhibitors (TKIs). While some non-small cell lung cancer (NSCLC) patients harboring special subtypes of EGFR ex20ins still achieved clinical response after TKIs treatment, ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Ling, Wu, Xiaomai, Yan, Shuangquan, Zhu, Yefei, Yan, Zhengqing, Lv, Dongqing, Ge, Hongfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533245/
https://www.ncbi.nlm.nih.gov/pubmed/33061454
http://dx.doi.org/10.2147/OTT.S268694
_version_ 1783590089689923584
author Lin, Ling
Wu, Xiaomai
Yan, Shuangquan
Zhu, Yefei
Yan, Zhengqing
Lv, Dongqing
Ge, Hongfei
author_facet Lin, Ling
Wu, Xiaomai
Yan, Shuangquan
Zhu, Yefei
Yan, Zhengqing
Lv, Dongqing
Ge, Hongfei
author_sort Lin, Ling
collection PubMed
description PURPOSE: Most epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are resistant to tyrosine kinase inhibitors (TKIs). While some non-small cell lung cancer (NSCLC) patients harboring special subtypes of EGFR ex20ins still achieved clinical response after TKIs treatment, identifying special subtypes of EGFR ex20ins is helpful to find out NSCLC patients who can respond to TKIs. CASE PRESENTATION: A 71-year-old non-smoker Chinese female was diagnosed with advanced lung adenocarcinoma harboring EGFR ex20ins (N771delinsKG). The patient received first-line afatinib (40 mg/day) therapy and a significant and substantial reduction in tumor size was observed subsequently. According to RESIST 1.1, a radiological partial response was achieved. The final progression-free survival was 10 months. CONCLUSION: This is the first published case report of EGFR N771delinsKG lung adenocarcinoma, which highlighted the heterogeneity of clinical response to TKIs for EGFR ex20ins-mutant NSCLC. Such results need to be further investigated in prospective studies.
format Online
Article
Text
id pubmed-7533245
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75332452020-10-14 Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations Lin, Ling Wu, Xiaomai Yan, Shuangquan Zhu, Yefei Yan, Zhengqing Lv, Dongqing Ge, Hongfei Onco Targets Ther Case Report PURPOSE: Most epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are resistant to tyrosine kinase inhibitors (TKIs). While some non-small cell lung cancer (NSCLC) patients harboring special subtypes of EGFR ex20ins still achieved clinical response after TKIs treatment, identifying special subtypes of EGFR ex20ins is helpful to find out NSCLC patients who can respond to TKIs. CASE PRESENTATION: A 71-year-old non-smoker Chinese female was diagnosed with advanced lung adenocarcinoma harboring EGFR ex20ins (N771delinsKG). The patient received first-line afatinib (40 mg/day) therapy and a significant and substantial reduction in tumor size was observed subsequently. According to RESIST 1.1, a radiological partial response was achieved. The final progression-free survival was 10 months. CONCLUSION: This is the first published case report of EGFR N771delinsKG lung adenocarcinoma, which highlighted the heterogeneity of clinical response to TKIs for EGFR ex20ins-mutant NSCLC. Such results need to be further investigated in prospective studies. Dove 2020-09-30 /pmc/articles/PMC7533245/ /pubmed/33061454 http://dx.doi.org/10.2147/OTT.S268694 Text en © 2020 Lin et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Lin, Ling
Wu, Xiaomai
Yan, Shuangquan
Zhu, Yefei
Yan, Zhengqing
Lv, Dongqing
Ge, Hongfei
Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
title Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
title_full Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
title_fullStr Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
title_full_unstemmed Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
title_short Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
title_sort response to afatinib in a patient with nsclc harboring novel egfr exon 20 insertion mutations
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533245/
https://www.ncbi.nlm.nih.gov/pubmed/33061454
http://dx.doi.org/10.2147/OTT.S268694
work_keys_str_mv AT linling responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations
AT wuxiaomai responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations
AT yanshuangquan responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations
AT zhuyefei responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations
AT yanzhengqing responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations
AT lvdongqing responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations
AT gehongfei responsetoafatinibinapatientwithnsclcharboringnovelegfrexon20insertionmutations